2021年2月23日 · We developed a qualitative hSBA-based assay that uses endogenous complement present in the serum of each individual (enc-hSBA). This enables testing on …

2015年8月26日 · The “gold standard” for measuring the ability of vaccine-induced antibody to kill Neisseria meningitidis is the serum bactericidal antibody (SBA) assay which measures …

The hSBA assay using a pooled human complement source is a practical, reliable method for assessing immune responses to meningococcal vaccines and can generate data that may …

These observations collectively suggest that rSBA assays are a more appropriate method than hSBA assays for measuring immune responses and antibody persistence to MenACWY-TT, …

Immunogenicity of vaccines against meningococcal serogroup B (MenB) has been assessed pre-licensure with a human serum bactericidal activity assay (hSBA), tested against small …

2025年1月1日 · In an effort to elucidate the utility of SBA as an immune correlate of protection, we sought to develop a standardized high-throughput human complement SBA (hSBA) assay for …

Instead, an indirect measure, called the ‘hSBA assay' (serum bactericidal antibody assay using human complement), is used to measure the ability of vaccines to provide protection against …

2011年12月9日 · The surrogate of protection against invasive meningococcal disease is the presence of serum bactericidal activity (SBA) at a titer ≥4 in an assay using human serum as …

An SBA titre of ≥4 using human serum as the exogenous complement source (hSBA) is the established correlate of protection against invasive meningococcal disease [25,27].

Immunogenicity of vaccines against meningococcal serogroup B (MenB) has been assessed pre-licensure with a human serum bactericidal activity assay (hSBA), tested against small …